Janssen Pharmaceuticals Inc. faces a woman’s partial foot amputation lawsuit. The lawsuit joins a growing multidistrict litigation (MDL) filed against the company over Invokana.

The partial foot amputation lawsuit was filed in New Jersey federal court on June 12, 2018.

According to the partial foot amputation lawsuit, plaintiff Carey L. is a resident and citizen of Defuniak Springs, Fla. She says that she began taking Invokana in February 2014. She says began taking Invokana in an effort to reduce her blood sugar levels and control her Type 2 diabetes.

However, on June 17, 2017, she alleges suffered from a transmetatarsal amputation of the right foot. As a result, she was hospitalized and required substantial medical treatment, the lawsuit contends.

According to the lawsuit, her “injuries was preventable and resulted directly from … [Janssen’s] failure and refusal to conduct proper safety studies, failure to properly assess and publicize alarming safety signals, suppression of information revealing serious and life-threatening risks, willful and wanton failure to provide adequate instructions, and willful misrepresentations concerning the nature and safety of Invokana, “the lawsuit states.

The partial foot amputation lawsuit was filed on multiple counts including strict liability, manufacturing defect, design defect, failure to warn, negligence, breach of express warranty, breach of implied warranty, negligent misrepresentation, fraudulent misrepresentation, unjust enrichment, fraud, violation of consumer protection laws, and punitive damages.

Overview: Partial Foot Amputation

Thousands of patients like Carey file partial foot amputation lawsuits against Janssen Pharmaceuticals alleging they suffered severe adverse side effects and complications linked to the type-2 diabetes medication. Adverse side effects and complications reportedly include toe amputation side effects, pancreatitis, bone fractures, kidney problems, and cardiovascular side effects, among others.

The filing of a partial foot amputation lawsuit can help individuals recover losses related to medical expenses and lost wages, not to mention pain and suffering.

Some adverse side effects linked to Invokana include:

• Amputation Risks
• Diabetic Ketoacidosis (DKA)
• Lactic Acidosis
• Kidney and Blood Infections
• Acute Kidney Injury Warning

The U.S. Food and Drug Administration (FDA) continues to receive adverse event reports because of serious injuries associated with Invokana. Invokana (canagliflozin) is part of a sodium-glucose transport inhibitors class that became approved by the FDA on March 29, 2013. However, severe side effects and conditions such as diabetic ketoacidosis, kidney injuries, bone fractures, and more recently amputation continues to be linked to the medication.

The agency recently reported between foot and toe amputation side effects due to Invokana intake. According to the FDA, “Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations,” the agency said.

We are “requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk,” they added.

The Partial Foot Amputation Lawsuit is Case No. 3:18-cv-10459-BRM-LHG, in the U.S. District Court for the District of New Jersey. The Invokana Lawsuit is MDL No. 2750 is in re: Invokana (Canagliflozin) Products Liability Litigation, in the U.S. District Court for the District of New Jersey.